Related Experiment Video
Updated: Jan 9, 2026
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Sirolimus for the treatment of Graves' orbitopathy
Simone Comi1, Elena Sabini1, Giada Cosentino1
1Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, Pisa, 56124, Italy.
Objectives:
A role of mTOR (mammalian target of rapamycin) in the pathogenesis of Graves' Orbitopathy (GO) has been proposed and rapamycin, better known as sirolimus, an mTOR inhibitor, was recently used in patients with GO. Here we review the available studies evaluating the role of mTOR in GO pathogenesis and the effects of sirolimus on GO.
Design:
A comprehensive search of PubMed was conducted using the following keywords: "Graves' orbitopathy", or "thyroid eye disease", or "Graves' ophthalmopathy", or "thyroid-associated ophthalmopathy"; and: "mTOR", or "sirolimus", or "rapamycin".
Inclusion Criteria:
1) original articles (preclinical and clinical studies); 2) English language. The articles that did not adequately explore the role of mTOR in GO pathogenesis and those in which the effects of sirolimus on GO were not investigated were excluded. At the end of the screening process, nine studies were included in this systematic review.
Results:
mTOR signaling pathway was found to be upregulated in patients with GO. In addition, studies in a mouse model of GO, in orbital fibroblasts and peripheral blood mononuclear cells (PBMCs) derived from GO patients showed a significant reduction in inflammatory mediators, adipogenesis and fibrosis after treatment with sirolimus. In 2007 and 2019 two cases of patients with GO unresponsive to glucocorticoids and successfully treated with sirolimus were described. Consistently with these results, two retrospective investigations showed that treatment with sirolimus, used at low dosage for 12 weeks, was followed by a greater overall response of GO compared with methylprednisolone at 24 weeks. In addition, a good response in diplopia and ocular motility restriction after treatment with sirolimus was reported by two case series. All of these studies reported a good tolerability of sirolimus. Finally, GO response to treatment was shown to correlate with the serum levels of sirolimus at the end of treatment.
Conclusions:
Sirolimus may represent a cheap, effective, and safe alternative treatment for GO. In addition, serum levels of sirolimus may be used to predict the response to treatment. Randomized clinical trials are needed to confirm the efficacy of sirolimus on GO and establish the best possible treatment protocol.
Insights
Sirolimus (an mTOR inhibitor) shows promise for treating Graves' orbitopathy (GO). Studies indicate it reduces inflammation and fibrosis, offering an effective and safe alternative to current treatments for this thyroid eye disease.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Graves' orbitopathy (GO) is an autoimmune condition affecting the eyes.
- The mammalian target of rapamycin (mTOR) signaling pathway is implicated in GO pathogenesis.
- Sirolimus, an mTOR inhibitor, has emerged as a potential therapeutic agent for GO.
Purpose of the Study:
- To review existing literature on the role of mTOR in GO.
- To evaluate the efficacy and safety of sirolimus in treating GO patients.
Main Methods:
- A comprehensive PubMed search was performed using keywords related to Graves' orbitopathy and mTOR/sirolimus.
- Included studies were original articles (preclinical and clinical) in English.
- Nine studies were selected for this systematic review.
Main Results:
- mTOR signaling is upregulated in GO patients.
- Sirolimus treatment reduced inflammatory mediators, adipogenesis, and fibrosis in GO models and patient cells.
- Clinical cases and retrospective studies showed sirolimus to be effective, with good tolerability and a potential correlation between serum levels and treatment response.
Conclusions:
- Sirolimus presents a potentially cost-effective, safe, and effective treatment option for Graves' orbitopathy.
- Serum sirolimus levels may predict treatment outcomes.
- Further randomized clinical trials are necessary to confirm efficacy and optimize treatment protocols.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:28Angle Closure Glaucoma: Treatment
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:25Glaucoma: Overview
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...